Melissa L Abel, Nobuyuki Takahashi, Cody Peer, Christophe E Redon, Samantha Nichols, Rasa Vilimas, Min-Jung Lee, Sunmin Lee, Meenakshi Shelat, Robbie Kattappuram, Linda Sciuto, Danielle Pinkiert, Chante Graham, Donna Butcher, Baktiar Karim, Ajit Kumar Sharma, Justin Malin, Rajesh Kumar, Christopher W Schultz, Shubhank Goyal, Jaydira Del Rivero, Manan Krishnamurthy, Deep Upadhyay, Brett Schroeder, Tristan Sissung, Manoj Tyagi, Jung Kim, Yves Pommier, Mirit Aladjem, Mark Raffeld, William Douglas Figg, Jane Trepel, Liqiang Xi, Parth Desai, Anish Thomas
PURPOSE: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. PATIENTS AND METHODS: In a phase I trial, we combined sacituzumab govitecan, antibody-drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib...
May 25, 2023: Clinical Cancer Research